SUPERNUS PHARMACEUTICALS, INC. Convertible Notes Payable, Noncurrent
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Convertible Notes Payable, Noncurrent of $0 as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:ConvertibleLongTermNotesPayable · last filed 2023-03-09
- 2022-12-31: Convertible Notes Payable, Noncurrent $0.00.
- 2022-03-31: Convertible Notes Payable, Noncurrent $400.38M.
- 2021-12-31: Convertible Notes Payable, Noncurrent $379.25M.
- 2021-09-30: Convertible Notes Payable, Noncurrent $374.79M.
| Period end | Convertible Notes Payable, Noncurrent | Convertible Notes Payable, Noncurrent as first filed |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2022-03-31 | $400.38M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $379.25M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $374.79M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $370.38M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $366.04M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $361.75M 10-K · filed 2022-04-13 | |
| 2020-09-30 | $357.52M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $353.35M 10-Q · filed 2020-08-17 | |
| 2020-03-31 | $349.23M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $345.17M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $341.16M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $337.21M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $333.31M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $329.46M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $325.67M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $321.92M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $318.23M 10-Q · filed 2018-05-10 | |
| 2017-06-30 | $1.47M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $3.31M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $4.17M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $5.77M 10-Q · filed 2017-01-20 | |
| 2016-06-30 | $5.70M 10-Q/A · filed 2017-01-23 | |
| 2016-03-31 | $5.63M 10-Q/A · filed 2017-01-20 | |
| 2015-12-31 | $7.08M 10-K · filed 2017-03-16 | $7.19M 10-K · filed 2016-03-09 |
| 2015-09-30 | $7.94M 10-Q/A · filed 2017-01-20 | $8.07M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $8.61M 10-Q/A · filed 2017-01-23 | $8.76M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $11.48M 10-Q/A · filed 2017-01-20 | $11.71M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $26.22M 10-Q/A · filed 2017-01-20 | $26.95M 10-K · filed 2015-03-12 |
| 2014-09-30 | $25.73M 10-Q/A · filed 2017-01-20 | $26.50M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $28.67M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $28.36M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $34.39M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $60.17M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $59.10M 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |